TAK
TAKEDA PHARMACEUTICAL CO LTD
$15.74
+0.90%
$49.5B
No data for this timeframe.
Vol
Market Cap$49.5B
Cap SizeLarge Cap
Inst. Holders7 funds
Inst. Value$233.7M
Inst. Activity0 buys / 1 sells
Recent Activity
Jun 9, 2026
short_volume
Short Volume: TAK — 73.1% short (1.4M / 1.9M)
Short: 1,396,105 | Exempt: 657 | TRF Vol: 1,908,805 | Short Ratio: 73.1% | Off-exchange volume (dark
Apr 27, 2026
Insider
Kim Julie So-Young sold 105,416 shares
CEO - Elect @ $0.00 ($0.00)
Apr 27, 2026
Insider
Furuta Milano sold 7,800 shares
Chief Financial Officer @ $0.00 ($0.00)
Apr 27, 2026
Insider
Furuta Milano sold 7,814 shares
Chief Financial Officer @ $0.00 ($0.00)
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
2,618,300 shares ($40.8M)
Inst.
UBS Group AG — ADD
5,893,969 shares ($86.3M)
Apr 23, 2026
Event
MYDAYIS
Supplemental Approval — Labeling — DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAM
Price Targets
Historical data — last covering-analyst action May 2023. No current recommendation available.
$20.67 (May 2023)
Current $15.72
Low $19.39
Median $20.95
High $21.66
3 analysts
$19.39
$21.66
Analyst Ratings
5Strong Buy
8Buy
6Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 16, 2023 | TD Cowen | MAINTAIN | Outperform → Outperform |
| Apr 4, 2023 | TD Cowen | MAINTAIN | Outperform |
| Mar 16, 2023 | B of A Securities | UPGRADE | Neutral → Buy |
| Jul 19, 2022 | Cowen & Co. | UPGRADE | Market Perform → Outperform |
| Oct 7, 2021 | Morgan Stanley | DOWNGRADE | Overweight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $50.77 ▼ -46.2% | $50.77 — $50.77 | -17% YoY | 1 |
| Next FY | $109.43 | $109.43 — $109.43 | 116% YoY | 1 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $99.4M | ADD |
| FMR LLC | $63.2M | — |
| RENAISSANCE TECHNOLOGIES LLC | $40.8M | TRIM |
| WELLS FARGO & COMPANY/MN | $16.5M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $6.4M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 27, 2026 | Kim Julie | A | $0.00 |
| Apr 27, 2026 | Furuta Milano | A | $0.00 |
| Apr 27, 2026 | Furuta Milano | A | $0.00 |
| Apr 27, 2026 | Ricci Gabriele | A | $0.00 |
| Apr 27, 2026 | Bitetti Teresa | A | $0.00 |
7 institutional holders with $233.7M total value (14,987,261 shares) as of 2025-Q4. Top holders: MORGAN, FMR, RENAISSANCE. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 6,373,202 | $99.4M | 42.5% | ADD +33.6% |
| 2 | FMR LLC | 4,056,868 | $63.2M | 27.1% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 2,618,300 | $40.8M | 17.5% | TRIM -32.2% |
| 4 | WELLS FARGO & COMPANY/MN | 1,060,461 | $16.5M | 7.1% | — |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 413,692 | $6.4M | 2.8% | ADD +35.5% |
| 6 | BANK OF AMERICA CORP /DE/ | 362,868 | $5.7M | 2.4% | TRIM -64.5% |
| 7 | VANGUARD GROUP INC | 101,870 | $1.6M | 0.7% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 3,864,600 | 2,618,300 | -32.2% | $40.8M | 2025-Q4 |
| UBS Group AG | ADD | 4,024,646 | 5,893,969 | +46.4% | $86.3M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,037,163 | 368,350 | -64.5% | $5.4M | 2025-Q3 |
| MORGAN STANLEY | ADD | 5,702,524 | 7,619,590 | +33.6% | $117.8M | 2025-Q2 |
| UBS Group AG | DOUBLED | 1,754,562 | 4,024,646 | +129.4% | $62.2M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 318,358 | 1,037,163 | +225.8% | $16.0M | 2025-Q2 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 1,731,489 | 194,456 | -88.8% | $2.9M | 2025-Q1 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | EXIT | 522,030 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 73,015 | 1,661,632 | +2175.7% | $22.0M | 2024-Q4 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | TRIM | 1,281,192 | 522,030 | -59.3% | $6.9M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 187,165 | 253,551 | +35.5% | $3.4M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 187,165 | — | $2.7M | 2024-Q3 |
9 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 27, 2026 | Kim Julie So-Young | CEO - Elect | A | 105,416 | $0.00 | $0.00 |
| Apr 27, 2026 | Furuta Milano | Chief Financial Officer | A | 7,800 | $0.00 | $0.00 |
| Apr 27, 2026 | Furuta Milano | Chief Financial Officer | A | 7,814 | $0.00 | $0.00 |
| Apr 27, 2026 | Ricci Gabriele | Chief Data & Tech. Officer | A | 34,994 | $0.00 | $0.00 |
| Apr 27, 2026 | Bitetti Teresa Marie | President, OBU | A | 64,988 | $0.00 | $0.00 |
| Apr 27, 2026 | Duprey Lauren Rusckowski | Chief Transformation Officer | A | 59,990 | $0.00 | $0.00 |
| Apr 27, 2026 | Platford Giles Richard | President, IBU | A | 72,124 | $0.00 | $0.00 |
| Apr 27, 2026 | Pignagnoli Agosti Marcello | Head, Strat. & Port. Dev. | A | 27,740 | $0.00 | $0.00 |
| Apr 27, 2026 | Plump Andrew Stewart | President, R&D | A | 212,470 | $0.00 | $0.00 |
| Apr 27, 2026 | Weber Christophe Pierre | President and CEO | A | 78,900 | $0.00 | $0.00 |
| Apr 27, 2026 | Weber Christophe Pierre | President and CEO | A | 165,370 | $0.00 | $0.00 |
| Apr 27, 2026 | Weber Christophe Pierre | President and CEO | A | 78,978 | $0.00 | $0.00 |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action May 2023): 68% buy across 19 analysts — 5 strong buy, 8 buy, 6 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action May 2023. No current recommendation available.
$20.67 mean target (May 2023)
$19.39 Low
$21.66 High
| Metric | Value |
|---|---|
| Current Price | $15.72 |
| Target Low | $19.39 |
| Target Mean | $20.67 |
| Target Median | $20.95 |
| Target High | $21.66 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $1161.5B | 5.0% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $1165.1B | 4.7% | — |
| Current FY 2027-03-31 |
$50.77 | $50.77 | $50.77 | -16.8% | -46.2% | 0↑ 1↓ | $4620.5B | 681.0% | 1 |
| Next FY 2028-03-31 |
$109.43 | $109.43 | $109.43 | 115.5% | — | — | $4692.9B | 1.6% | 1 |
6 analyst firms have rated this stock: 2 upgrades, 1 downgrades, 2 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 16, 2023 | TD Cowen | MAINTAIN | Outperform | Outperform |
| Apr 4, 2023 | TD Cowen | MAINTAIN | — | Outperform |
| Mar 16, 2023 | B of A Securities | UPGRADE | Neutral | Buy |
| Jul 19, 2022 | Cowen & Co. | UPGRADE | Market Perform | Outperform |
| Oct 7, 2021 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Mar 11, 2020 | JP Morgan | MAINTAIN | — | Overweight |
| Nov 1, 2019 | Cowen & Co. | INITIATE | — | Market Perform |
| Sep 24, 2019 | Jefferies | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 8 | 6 | 0 | 0 | 68% | |
| May 1, 2026 | 5 | 8 | 6 | 0 | 0 | 68% | |
| Apr 1, 2026 | 3 | 8 | 8 | 0 | 0 | 58% | |
| Mar 1, 2026 | 3 | 8 | 8 | 0 | 0 | 58% | |
| Feb 1, 2026 | 3 | 8 | 8 | 0 | 0 | 58% | |
| Jan 1, 2026 | 3 | 7 | 8 | 0 | 0 | 56% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 10, 2026
Clinical Trial
A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome
Phase Phase 3 — TERMINATED
Jun 9, 2026
short_volume
Short Volume: TAK — 73.1% short (1.4M / 1.9M)
Short: 1,396,105 | Exempt: 657 | TRF Vol: 1,908,805 | Short Ratio: 73.1% | Off-exchange volume (dark pool + OTC)
Jun 7, 2026
Clinical Trial
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Phase Phase 2 — COMPLETED
Jun 7, 2026
clinical_trial_readout
Results Pending: Dazostinag (Phase 2) — Completed 69d ago
Trial: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Spons
Jun 5, 2026
short_volume
Short Volume: TAK — 63.3% short (0.8M / 1.3M)
Short: 806,397 | Exempt: 1 | TRF Vol: 1,272,990 | Short Ratio: 63.3% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: TAK — 56.4% short (0.6M / 1.0M)
Short: 583,683 | Exempt: 3,720 | TRF Vol: 1,035,556 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: TAK — 70.4% short (0.7M / 1.0M)
Short: 691,801 | Exempt: 200 | TRF Vol: 982,750 | Short Ratio: 70.4% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
Clinical Trial
A Study of TAK-341 in Treatment of Multiple System Atrophy
Phase Phase 2 — COMPLETED
Jun 1, 2026
Clinical Trial
A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Jun 1, 2026
clinical_trial_readout
T-90d Trial Readout: Tetravalent Dengue Vaccine (TDV) (Phase 3)
Trial: A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults
Sponsor: Takeda
Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITING
May 31, 2026
Clinical Trial
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
Phase Phase 3 — COMPLETED
May 31, 2026
clinical_trial_readout
Results Pending: Zasocitinib (Phase 3) — Completed 39d ago
Trial: A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
Sponsor: Takeda
Phase: Phase 3 | Completed: 2026-0
May 29, 2026
short_volume
Short Volume: TAK — 58.0% short (0.5M / 0.8M)
Short: 468,145 | Exempt: 220 | TRF Vol: 807,839 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
May 28, 2026
clinical_trial_readout
Results Pending: TAK-755 (Phase 2) — Completed 42d ago
Trial: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Pur
May 27, 2026
short_volume
Short Volume: TAK — 56.8% short (0.7M / 1.3M)
Short: 737,647 | Exempt: 836 | TRF Vol: 1,299,488 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: TAK — 58.8% short (0.8M / 1.3M)
Short: 751,915 | Exempt: 142 | TRF Vol: 1,278,787 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: TAK — 70.9% short (0.9M / 1.3M)
Short: 890,037 | Exempt: 0 | TRF Vol: 1,254,821 | Short Ratio: 70.9% | Off-exchange volume (dark pool + OTC)
May 15, 2026
clinical_trial_readout
Results Pending: Vonicog alfa (Phase 3) — Completed 28d ago
Trial: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
Sponsor: Baxalt
May 8, 2026
clinical_trial_readout
Results Pending: Dazostinag (Phase 2) — Completed 39d ago
Trial: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Spons
May 7, 2026
short_interest
FTD: TAK — 101,304 shares ($1.7M) failed to deliver
Settlement: 20260507, Price: $16.72, FTD Value: $1,693,802.88, TAKEDA PHARMACEUTICAL CO LTD S
Apr 23, 2026
FDA
MYDAYIS
Supplemental Approval — Labeling — DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, AND AMPHETAMINE SULFATE
Apr 18, 2005
FDA
ANAGRELIDE HYDROCHLORIDE
Apr 18, 2005
FDA
ANAGRELIDE HYDROCHLORIDE